1124 related articles for article (PubMed ID: 29424927)
21. Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning.
Hari P; Carreras J; Zhang MJ; Gale RP; Bolwell BJ; Bredeson CN; Burns LJ; Cairo MS; Freytes CO; Goldstein SC; Hale GA; Inwards DJ; Lemaistre CF; Maharaj D; Marks DI; Schouten HC; Slavin S; Vose JM; Lazarus HM; van Besien K
Biol Blood Marrow Transplant; 2008 Feb; 14(2):236-45. PubMed ID: 18215784
[TBL] [Abstract][Full Text] [Related]
22. Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma.
Klyuchnikov E; Bacher U; Woo Ahn K; Carreras J; Kröger NM; Hari PN; Ku GH; Ayala E; Chen AI; Chen YB; Cohen JB; Freytes CO; Gale RP; Kamble RT; Kharfan-Dabaja MA; Lazarus HM; Martino R; Mussetti A; Savani BN; Schouten HC; Usmani SZ; Wiernik PH; Wirk B; Smith SM; Sureda A; Hamadani M
Bone Marrow Transplant; 2016 Jan; 51(1):58-66. PubMed ID: 26437062
[TBL] [Abstract][Full Text] [Related]
23. Myeloablative intravenous pharmacokinetically targeted busulfan plus fludarabine as conditioning for allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma.
Ayala E; Figueroa J; Perkins J; Kim J; Yue B; Riches M; Nishihori T; Locke F; Anasetti C; Kharfan-Dabaja MA
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):335-40. PubMed ID: 25659459
[TBL] [Abstract][Full Text] [Related]
24. Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC).
Vigouroux S; Michallet M; Porcher R; Attal M; Ades L; Bernard M; Blaise D; Tabrizi R; Garban F; Cassuto JP; Chevalier P; Facon T; Ifrah N; Renaud M; Tilly H; Vernant JP; Kuentz M; Bourhis JH; Bordigoni P; Deconinck E; Lioure B; Socié G; Milpied N;
Haematologica; 2007 May; 92(5):627-34. PubMed ID: 17488686
[TBL] [Abstract][Full Text] [Related]
25. Relapse and survival after transplantation for complex karyotype acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and the University of Texas MD Anderson Cancer Center.
Ciurea SO; Labopin M; Socie G; Volin L; Passweg J; Chevallier P; Beelen D; Milpied N; Blaise D; Cornelissen JJ; Fegueux N; Polge E; Kongtim P; Rondon G; Esteve J; Mohty M; Savani BN; Champlin RE; Nagler A
Cancer; 2018 May; 124(10):2134-2141. PubMed ID: 29469961
[TBL] [Abstract][Full Text] [Related]
26. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
27. Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis.
Epperla N; Ahn KW; Litovich C; Ahmed S; Battiwalla M; Cohen JB; Dahi P; Farhadfar N; Farooq U; Freytes CO; Ghosh N; Haverkos B; Herrera A; Hertzberg M; Hildebrandt G; Inwards D; Kharfan-Dabaja MA; Khimani F; Lazarus H; Lazaryan A; Lekakis L; Murthy H; Nathan S; Nishihori T; Pawarode A; Prestidge T; Ramakrishnan P; Rezvani AR; Romee R; Shah NN; Sureda A; Fenske TS; Hamadani M
J Hematol Oncol; 2019 Jan; 12(1):6. PubMed ID: 30630534
[TBL] [Abstract][Full Text] [Related]
28. Allogeneic transplantation for relapsed and refractory Hodgkin lymphoma: long-term outcomes and graft-versus-host disease-free/relapse-free survival.
Spina F; Radice T; De Philippis C; Soldarini M; Di Chio MC; Dodero A; Guidetti A; Viviani S; Corradini P
Leuk Lymphoma; 2019 Jan; 60(1):101-109. PubMed ID: 29716416
[TBL] [Abstract][Full Text] [Related]
29. (90)Y-ibritumomab tiuxetan followed by reduced-intensity conditioning and allo-SCT in patients with advanced follicular lymphoma.
Abou-Nassar KE; Stevenson KE; Antin JH; McDermott K; Ho VT; Cutler CS; LaCasce AS; Jacobsen ED; Fisher DC; Soiffer RJ; Alyea EP; Koreth J; Freedman AS
Bone Marrow Transplant; 2011 Dec; 46(12):1503-9. PubMed ID: 21258420
[TBL] [Abstract][Full Text] [Related]
30. Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: a multicenter retrospective study based on donor availability.
Patriarca F; Einsele H; Spina F; Bruno B; Isola M; Nozzoli C; Nozza A; Sperotto A; Morabito F; Stuhler G; Festuccia M; Bosi A; Fanin R; Corradini P
Biol Blood Marrow Transplant; 2012 Apr; 18(4):617-26. PubMed ID: 21820394
[TBL] [Abstract][Full Text] [Related]
31. Allogeneic hematopoietic cell transplantation as curative therapy for non-transformed follicular lymphomas.
Heinzelmann F; Bethge W; Beelen DW; Engelhard M; Kröger N; Dreger P; Niederwieser D; Finke J; Bunjes D; Tischer J; Kobbe G; Holler E; Bornhäuser M; Stelljes M; Baurmann H; Müller A; Haubitz I; Schrezenmeier H; Müller C; Ottinger H
Bone Marrow Transplant; 2016 May; 51(5):654-62. PubMed ID: 26855152
[TBL] [Abstract][Full Text] [Related]
32. Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?
Bacher U; Klyuchnikov E; Le-Rademacher J; Carreras J; Armand P; Bishop MR; Bredeson CN; Cairo MS; Fenske TS; Freytes CO; Gale RP; Gibson J; Isola LM; Inwards DJ; Laport GG; Lazarus HM; Maziarz RT; Wiernik PH; Schouten HC; Slavin S; Smith SM; Vose JM; Waller EK; Hari PN;
Blood; 2012 Nov; 120(20):4256-62. PubMed ID: 23007405
[TBL] [Abstract][Full Text] [Related]
33. Baseline Characteristics Predicting Very Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Patients With High Cytogenetic Risk Chronic Lymphocytic Leukemia - A Retrospective Analysis From the Chronic Malignancies Working Party of the EBMT.
van Gelder M; Ziagkos D; de Wreede L; van Biezen A; Dreger P; Gramatzki M; Stelljes M; Andersen NS; Schaap N; Vitek A; Beelen D; Lindström V; Finke J; Passweg J; Eder M; Machaczka M; Delgado J; Krüger W; Raida L; Socié G; Jindra P; Afanasyev B; Wagner E; Chalandon Y; Henseler A; Schoenland S; Kröger N; Schetelig J;
Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):667-675.e2. PubMed ID: 28694085
[TBL] [Abstract][Full Text] [Related]
34. Alternate donor hematopoietic cell transplantation (HCT) in non-Hodgkin lymphoma using lower intensity conditioning: a report from the CIBMTR.
Hale GA; Shrestha S; Le-Rademacher J; Burns LJ; Gibson J; Inwards DJ; Freytes CO; Bolwell BJ; Hsu JW; Slavin S; Isola L; Rizzieri DA; Gale RP; Laport GG; Montoto S; Lazarus HM; Hari PN
Biol Blood Marrow Transplant; 2012 Jul; 18(7):1036-1043.e1. PubMed ID: 22155506
[TBL] [Abstract][Full Text] [Related]
35. Favorable overall survival with fully myeloablative allogeneic stem cell transplantation for follicular lymphoma.
Kuruvilla J; Pond G; Tsang R; Gupta V; Lipton JH; Messner HA
Biol Blood Marrow Transplant; 2008 Jul; 14(7):775-82. PubMed ID: 18541196
[TBL] [Abstract][Full Text] [Related]
36. Clinical characteristics and outcomes of relapsed follicular lymphoma after autologous stem cell transplantation in the rituximab era.
Sesques P; Bourcier J; Golfier C; Lebras L; Nicolas-Virelizier E; Hacini M; Perrin MC; Voillat L; Bachy E; Traverse-Glehen A; Moreau A; Martin L; Ramla S; Casasnovas O; Le Gouill S; Salles G; Ghesquières H
Hematol Oncol; 2020 Apr; 38(2):137-145. PubMed ID: 31953963
[TBL] [Abstract][Full Text] [Related]
37. Allogeneic hematopoietic cell transplant for peripheral T-cell non-Hodgkin lymphoma results in long-term disease control.
Zain J; Palmer JM; Delioukina M; Thomas S; Tsai NC; Nademanee A; Popplewell L; Gaal K; Senitzer D; Kogut N; O'Donnell M; Forman SJ
Leuk Lymphoma; 2011 Aug; 52(8):1463-73. PubMed ID: 21699453
[TBL] [Abstract][Full Text] [Related]
38. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: a single center experience.
Goker H; Ozdemir E; Uz B; Buyukasik Y; Turgut M; Serefhanoglu S; Aksu S; Sayinalp N; Haznedaroglu IC; Tekin F; Karacan Y; Unal S; Eliacik E; Isik A; Ozcebe OI
Transfus Apher Sci; 2013 Dec; 49(3):590-9. PubMed ID: 23981652
[TBL] [Abstract][Full Text] [Related]
39. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
40. Matched unrelated donor stem cell transplant in 131 patients with follicular lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
Avivi I; Montoto S; Canals C; Maertens J; Al-Ali H; Mufti GJ; Finke J; Schattenberg A; Fanin R; Cornelissen JJ; Vernant JP; Russell N; Beguin Y; Thomson K; Verdonck LF; Kobbe G; Tilly H; Socié G; Sureda A;
Br J Haematol; 2009 Dec; 147(5):719-28. PubMed ID: 19793383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
